Potential for Abuse of Hydrocodone Combination Products

Published Online: Monday, January 13, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses the appeal of hydrocodone combination products to drug abusers.
 
This is the third in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Purdue Pharma has announced the US commercial launch of its extended-release hydrocodone bitartrate (Hysingla ER), an opioid analgesic indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in patients for whom alternative treatment options are inadequate.
Pharmacy operations can be improved by investing in continuing education for pharmacy technicians.
Drug addiction is one thing, but diverting that poison onto the streets when pharmacists are told in no uncertain terms not to do so isn’t looked upon so forgivingly.
With so many NAPLEX review books on the market, how can you decide which one is best?
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$